Mesalamine-associated pleural effusion with pulmonary infiltration

Gp, Sesin; Mucciardi, Nick; Almeida, Sílvia D.

doi:10.1093/ajhp/55.21.2304

Cited by 17 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 47 cases of pulmonary dysfunction with sulfasalazine and mesalamine have been documented in the literature (9–50). The most common disease entity is eosinophilic pneumonia (9–16), which is defined as an infiltration of the lungs with eosinophils with or without excessive eosinophils in the peripheral blood (51).…”

Section: Drug‐induced Diseasementioning

confidence: 99%

“…Although it is possible that these patients may have eosinophilic pneumonia, a definitive diagnosis cannot be made. Three such cases of drug‐induced disease presented atypically with pleural effusions (44,38,48) and three with a false‐positive C‐antineutrophil cytoplasmic antibodies (ANCA) (42,45,46), which further complicated the diagnosis. Eosinophilic pleural effusions has been reported in one patient treated with mesalamine, and we have observed one patient treated with infliximab (Fig.…”

Section: Drug‐induced Diseasementioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Manifestations of Inflammatory Bowel Disease

Storch

Sachar²,

Katz

2003

Inflammatory Bowel Diseases

195

131

View full text Add to dashboard Cite

Extraintestinal manifestations of both Crohn's disease and ulcerative colitis (UC) have been well described, although pulmonary findings are often overlooked. We summarize the experience of more than 400 cases of pulmonary manifestations of inflammatory bowel disease (IBD). These manifestations will be categorized by disease mechanism into drug-induced disease, anatomic disease, over-lap syndromes, autoimmune disease, physiologic consequences of IBD, pulmonary function test abnormalities, and nonspecific lung disease. We intend to provide the clinician with a practical working update on the spectrum of pulmonary dysfunction associated with IBD.

show abstract

Section: Drug‐induced Diseasementioning

confidence: 99%

Section: Drug‐induced Diseasementioning

confidence: 99%

Pulmonary Manifestations of Inflammatory Bowel Disease

Storch

Sachar²,

Katz

2003

Inflammatory Bowel Diseases

195

131

View full text Add to dashboard Cite

show abstract

“…Chest radiograph patterns in drug‐induced lung disease are nonspecific and can manifest in multiple patterns such as reticular or nodular changes, interstitial infiltrates, peripheral or diffuse acinar infiltrates, pleural effusions, and rarely, pure hyperinflation as seen with bronchiolitis obliterans (23). Chest radiographs in mesalamine‐induced lung injury are also nonspecific, with a variety of manifestations, including interstitial infiltrates, consolidation, and pleural effusions (8,20,22,24). These abnormalities can be localized to the upper or lower lung zones.…”

Section: Discussionmentioning

confidence: 99%

“…These findings resolved in several weeks after discontinuation of 5‐aminosalicylic acid. Although pleural involvement is not common, there has been one report of mesalamine‐associated pleural effusion (24).…”

Section: Discussionmentioning

confidence: 99%

Mesalamine-Related Lung Disease: Clinical, Radiographic, and Pathologic Manifestations

Foster¹,

Zander

Mergo

et al. 2003

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Lung injury related to mesalamine (5-aminosalicylic acid) has rarely been reported in patients with inflammatory bowel diseases. Patients present with progressive respiratory symptoms and radiographic abnormalities whose genesis may occur from days to years after initiation of therapy. Although pathologic features overlap with other pulmonary disorders, findings of chronic interstitial pneumonia and poorly formed nonnecrotizing granulomas should prompt consideration of mesalamine-related lung disease in a patient receiving this medication. The authors describe the clinical, radiographic, and pathologic manifestations of mesalamine-related lung disease in three patients and review the literature related to this topic.

show abstract

“…Pulmonary function studies reveal a restrictive pattern, with a reduction of diffusing capacity for carbon monoxide (DL co ). Mesalazine related lung injury shows a variety of radiological manifestations, with interstitial infiltrates, consolidations (localized at the upper or lower lobes) and pleural effusions often described on standard chest X-ray study [14,15]. High resolution CT scan of the chest is particularly helpful to exclude mediastinal pathology, cavitations, pleural involvement and to better locate lung areas suitable for optimal tissue biopsy.…”

mentioning

confidence: 99%